Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Mylan warns of...

    Mylan warns of possible drug shortages, financial hit due to coronavirus

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-02-29T09:30:59+05:30  |  Updated On 29 Feb 2020 9:31 AM IST
    Mylan warns of possible drug shortages, financial hit due to coronavirus

    Although heavily reliant on China, the company said it was better positioned against the impact of the outbreak compared to its peers due to its diversified supply chain.

    Netherlands: Drugmaker Mylan NV said it expects the coronavirus outbreak to impact its financial results and warned of drug shortages in case of continued spread of the virus, sending shares of the company down 3.6%.

    The outbreak has so far mainly battered China, causing nearly 80,000 infections and more than 2,700 deaths, according to World Health Organization figures. It has spread to another 46 countries, where around 3,700 cases and 57 deaths have been reported.

    "Our business exposure in China specifically is limited. However, given the global nature of our supply chain, operations and businesses, our results could potentially be impacted," Chief Executive Officer Heather Bresch said on an earnings call.

    Mylan said it was facing logistical issues, but had not seen problems with production or experienced price increases in active drug ingredients.

    Although heavily reliant on China, the company said it was better positioned against the impact of the outbreak compared to its peers due to its diversified supply chain.

    "The whole industry is in one way or other way connected with China, but you would expect us to be much better placed," President Rajiv Malik said.

    Read also: USFDA identifies 20 drugs with shortage risks due to coronavirus outbreak

    Mylan said it does not see any impact in the near future, but cautioned that continued spread of the coronavirus over the next few months could lead to drug shortages.

    The company is set to merge with Pfizer Inc's China-headquartered Upjohn unit that houses off-patent branded drugs such as cholesterol drug Lipitor, allowing Mylan to leverage a strong base in Asia.

    Pfizer on Thursday also warned that continued spread of the virus could have an adverse impact on its financial results and operations, including its manufacturing, supply chain and clinical trial operations.

    Read also: Mylan, Pfizer say Mylan-Upjohn combined entity to be known as Viatris


    mylandrug-shortagecoronaviruscovid-19rajiv-malik
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok